Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia

(2011) Zeba Aziz et al.   LEUKEMIA & LYMPHOMA

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

(2010) Javier Pinilla-Ibarz et al.   CANCER

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine Kinase Inhibitors: The First Decade

(2010) Meetu Agrawal et al.   Current Hematologic Malignancy Reports

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

(2009) David Masiello et al.   Journal of Hematology & Oncology

Identifying Clinically Meaningful Fatigue with the Fatigue Symptom Inventory

(2008) Kristine A. Donovan et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT